Clinical trial / 2015
Maca root (3.0 g/day) resulted in higher remission rates of antidepressant-induced sexual dysfunction than placebo, particularly in postmenopausal women.
A 12-week double-blind, placebo-controlled trial evaluated maca root (3.0 g/day) in 45 female outpatients with remitted depression and SSRI/SNRI-induced sexual dysfunction, with 42 eligible for modified intent-to-treat analysis. Remission rates at the end of treatment were higher with maca than placebo for an ASEX score ≤ 10 (9.5% vs. 4.8%), an MGH-SFQ score ≤ 12 (30.0% vs. 20.0%), and an MGH-SFQ score ≤ 8 (9.5% vs. 5.0%). Higher remission rates with maca compared to placebo were associated with postmenopausal status. Maca was reported to be well tolerated.
- Study type
- 12-week double-blind placebo-controlled randomized trial
- Who was studied
- 45 female outpatients (mean age 41.5 ± 12.5 years) with remitted depression and SSRI/SNRI-induced sexual dysfunction (42 analyzed)
- What was measured
- Improvement in sexual functioning assessed by ASEX and MGH-SFQ
THE PAPER
A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women.
Dording CM, Schettler PJ, Dalton ED, Parkin SR, Walker RS, Fehling KB, Fava M, Mischoulon D. Evid Based Complement Alternat Med, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.